Flubromazepam pellets 5 mg – More information
Flubromazepam is a long-lasting psychoactive substance of the benzodiazepine class which produces anxiolytic, sedative, muscle relaxant, depressant and amnesic effects.
This compound was first made in 1960, but was never marketed and did not receive any further attention or study until late 2012. It has potential use for the short-term treatment of anxiety, insomnia, acute seizures, and the sedation of hospitalized patients. However, it is currently exclusively sold by online research chemical vendors for use as a recreational psychoactive substance and has not been formally studied. This means that any comments regarding its pharmacology are purely speculation based upon the subjective effects it induces and its structural similarity to triazolam, pyrazolam and other benzodiazepines.
It’s worth noting that the sudden discontinuation of benzodiazepines can be potentially dangerous or life-threatening for individuals regularly using for extended periods of time, sometimes resulting in seizures or death. It is highly recommended to taper one’s dose by gradually lowering the amount taken each day for a prolonged period instead of stopping abruptly.
clinical data
Common names | Flubromazepam |
Systematic name | 7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one |
Psychoactive class | Depressant |
Chemical class | Benzodiazepine |
Flubromazepam dosage table
Threshold | 2 – 3 mg |
Light | 3 – 5 mg |
Common | 5 – 8 mg |
Strong | 8 – 12 mg |
Heavy | 12 – 16 mg + |
Flubromazepam effect progress
Total | 6 – 12 hours |
After effects | 24 hours |
Chemistry
Flubromazepam, or 7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one, is a chemical of the benzodiazepine class. Flubromazepam is named for the fluorine and bromine substitutions on its core benzodiazepine skeleton (FLUorine-BROMine-azepam). Flubromazepam is a member of the benzodiazepine class as it contains a 1,4 diazepine ring fused to a substituted benzene ring. Bromine is bound to this bicyclic structure at R7. Additionally, a fluorine-substituted phenyl ring is bound to this structure at R5. Flubromazepam also contains an oxygen group double bonded to R2 of its diazepine ring to form a ketone. This oxygen substitution at R2 is shared with other benzodiazepine drugs with the suffix -azepam.
Toxicity
Flubromazepam likely has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like alcohol or opioids.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance
Flubromazepam is extremely physically and psychologically addictive.
Tolerance will develop to the sedative-hypnotic effects within a couple of days of continuous use. After cessation, the tolerance returns to baseline in 7 – 14 days. However, in certain cases, this may take significantly longer in a manner which is proportional to the duration and intensity of one’s long-term usage.
Withdrawal symptoms or rebound symptoms may occur after ceasing usage abruptly following a few weeks or longer of steady dosing and may necessitate a gradual dose reduction. For more information on tapering from benzodiazepines in a controlled manner, please see this guide.
Benzodiazepine discontinuation is notoriously difficult; it is potentially life-threatening for individuals regularly using to discontinue use without tapering their dose over a period of weeks. There is an increased risk of hypertension, seizures, and death. Drugs which lower the seizure threshold such as tramadol should be avoided during withdrawal.
Flubromazepam presents cross-tolerance with all benzodiazepines, meaning that after its consumption, all benzodiazepines will have a reduced effect.
Overdose
Benzodiazepine overdose may occur when a benzodiazepine is taken in large quantities or concurrently with other depressants. This is particularly dangerous with other GABAergic depressants such as barbiturates and alcohol since they work similarly, but bind to distinct allosteric sites on the GABAA receptor. Thus their effects potentiate one another. Benzodiazepines increase the frequency in which the chlorine ion pore opens on the GABAA receptor while barbiturates increase the duration in which they are open, meaning when both are consumed, the ion pore will open more frequently and stay open longer. Benzodiazepine overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and appropriately.
Symptoms of a benzodiazepine overdose may include severe thought deceleration, slurred speech, confusion, delusions, respiratory depression, coma or death. Benzodiazepine overdoses may be treated effectively in a hospital environment, with generally favorable outcomes. Benzodiazepine overdoses are sometimes treated with flumazenil, a GABAA antagonist. However, care is primarily supportive in nature.
RalfR52 –
Ingenious bags, 5 stars